The platform, built by Ergün Yukmel Rasit, Raluca-Ioana Stefan-van Staden and Damaris-Cristina Gheorghe, relies on a so-called stochastic sensor constructed from a graphene–copper composite modified with α-cyclodextrin. Stochastic sensing is a distinct analytical paradigm: rather than producing a steady, averaged signal proportional to concentration, the device monitors the discrete interactions of individual analyte molecules with molecular-scale pores and binding sites on the electrode surface. Each interaction generates a characteristic current spike, and the statistical distribution of spike durations and amplitudes encodes both the identity and the quantity of the molecules present. This architecture allows the sensor to disentangle multiple species within the same sample, which is precisely what is needed when L-lysine and D-lysine must be resolved inside the complicated electrochemical matrix of whole blood.

The choice of materials is central to the sensor’s selectivity. Graphene provides an atomically thin, highly conductive two-dimensional scaffold with an enormous surface-to-volume ratio, ensuring that even vanishingly small numbers of adsorbed molecules produce measurable changes in electron transfer across the interface. Copper atoms incorporated into the composite act as additional coordination and redox centres, while α-cyclodextrin, a cyclic sugar ring with a hydrophobic cavity and hydrophilic rim, functions as the chiral recognition element. Because the cavity of α-cyclodextrin is itself asymmetric, it accommodates the two enantiomers of lysine with different binding geometries and different residence times. Those differences translate into distinct stochastic signatures in the recorded current traces, allowing the platform to quantify L- and D-lysine separately without any prior chemical separation of the sample.

The performance figures reported by the team are striking. For L-lysine, the working concentration range spans from 1.00×10⁻¹⁶ to 1.00×10⁻⁴ mol L⁻¹, with a sensitivity of 4.87×10¹³ mol L⁻¹ and a limit of determination of 1.00×10⁻¹⁶ mol L⁻¹, equivalent to 100 attomolar concentration. For D-lysine, the platform operates between 1.00×10⁻¹⁴ and 1.00×10⁻⁸ mol L⁻¹, with a sensitivity of 1.19×10¹⁰ mol L⁻¹ and a limit of determination of 1.00×10⁻¹⁴ mol L⁻¹. To place these numbers in perspective, conventional chiral analysis of amino acids is typically performed by liquid chromatography coupled to high-resolution tandem mass spectrometry, often after derivatization with chiral reagents and extensive sample cleanup. Such workflows consume time, expensive instrumentation and specialist personnel. The new platform, by contrast, delivers enantioselective readouts directly in undiluted whole blood, with recovery tests demonstrating values above 99.00 percent for both enantiomers regardless of the ratio in which they occur in the sample.

That recovery figure carries particular weight analytically. Enantiomeric ratios in biological fluids can shift dramatically in disease, so a sensor must remain accurate whether one form dominates or the two are nearly equal. Recovery values exceeding 99 percent across varying enantiomeric compositions indicate that the α-cyclodextrin recognition layer does not saturate preferentially, nor does the blood matrix suppress one signature while amplifying the other. It also suggests that fouling by proteins, cells and endogenous electroactive species, the usual bane of electrochemical measurements in raw blood, does not meaningfully degrade the stochastic response over the assay window.

The clinical motivation behind the work lies in the emerging field of chiral metabolomics. Lysine is an essential amino acid, meaning the human body cannot synthesize it and must obtain it from the diet. Beyond its structural role in proteins, lysine is a principal substrate for post-translational modifications, most notably acetylation and methylation of histones and transcription factors, processes that regulate gene expression and are frequently dysregulated in malignancy. Altered lysine acetylation patterns have been identified as both prognostic biomarkers and therapeutic targets in a range of cancers, and the enzymatic machinery that writes, reads and erases these marks is now a major focus of drug development. Changes in lysine availability and metabolism could therefore feed directly into the epigenetic state of a tumour cell.

Lung cancer is the specific disease context the researchers highlight. Case-control studies in non-small cell lung cancer have documented shifts in serum amino acid levels, suggesting that metabolic rewiring leaves detectable fingerprints in the circulation. At the same time, growing attention is being paid to D-amino acids, long dismissed as biologically irrelevant in humans but now implicated in signalling, immune modulation and, according to recent reviews, cancer diagnosis and therapy. Because the two enantiomers of an amino acid are chemically identical in every respect except handedness, they behave identically in standard assays and can only be told apart by chiral methods. A sensor that reads out the L-to-D ratio rapidly and cheaply could reveal metabolomic signatures invisible to conventional amino acid panels.

The Bucharest team has a track record in this area. Stefan-van Staden’s group previously reported enantioselective stochastic platforms for cysteine as a candidate marker in early breast cancer diagnosis, and for leucine and arginine in the context of lung cancer metabolomics, as well as three-dimensional stochastic sensor arrays for fast screening of whole blood and brain tissue in brain cancer. The new lysine platform extends that programme by combining chiral recognition with a two-dimensional, disposable format, an arrangement intended to make each measurement inexpensive enough for single-use clinical deployment, eliminating cross-contamination between samples and the need for electrode regeneration.

The technical design also reflects a deliberate trade-off. Traditional enantioseparation by liquid chromatography depends on chiral stationary phases, often cellulose- or amylose-based selectors, whose mechanistic principles have been refined over decades but which remain confined to centralized laboratories. Stochastic sensors approach the problem differently: the chiral selector is immobilized on the electrode itself, and discrimination occurs in the time domain of the current signal rather than in the spatial domain of a chromatogram. This collapses sample preparation, separation and detection into a single step and makes the measurement compatible with small volumes of finger-prick blood. The disposable nature of the platform means the sensing surface, including its graphene–copper composite and cyclodextrin layer, is engineered to be produced inexpensively and discarded after one assay.

Translational questions remain before such devices reach the clinic. Stochastic sensing requires careful statistical analysis of current-time traces, and the algorithms that assign signatures to specific enantiomers must be validated across large, diverse patient cohorts in which medications, diet and comorbidities all perturb the amino acid background. The extremely low limits of determination reported here were established under controlled conditions; demonstrating reproducibility across manufacturing batches of disposable platforms, and correlating lysine enantiomer ratios with confirmed lung cancer diagnoses in blinded studies, are the logical next steps. The work was supported by Romania’s Nucleus Program under the National Plan for Research, Development and Innovation 2022–2027, project PN 23 27 03 01.

Even so, the study adds a compelling datapoint to a broader movement in bioanalytical chemistry: the shift of sophisticated molecular measurements out of the core facility and onto cheap, single-use chips. Other groups have recently pursued molecularly imprinted electrochemical sensors for lysine in blood, fluorescent nanosensors that distinguish lysine enantiomers in dairy products, and metal-organic-framework-based probes for leukemia biomarkers. What distinguishes the new platform is its demonstrated ability to perform full enantioanalysis inside whole blood, the most demanding and clinically convenient of biological matrices, at concentrations fifteen orders of magnitude below molar. If subsequent clinical validation sustains that performance, the humble α-cyclodextrin ring, sitting on a graphene–copper film no thicker than a few atomic layers, could become a routine window into the chiral chemistry of cancer.

For researchers in metabolomics, the platform offers an immediate practical benefit: the ability to ask whether the L-to-D lysine ratio in a patient’s blood carries diagnostic or prognostic information, without first building a chromatography pipeline to answer the question. For clinicians, it sketches a future in which a single drop of blood, applied to a disposable strip, returns a chiral metabolite profile in minutes. Between those two horizons lies the familiar path of validation studies, regulatory review and manufacturing scale-up, but the analytical foundation, exquisite sensitivity, enantioselectivity and matrix tolerance in one disposable device, has now been laid.

At the molecular level, CRC development is conceptualized as a multistep evolutionary process characterized by sequential genetic insults. Key molecular pathways such as the adenoma-carcinoma sequence form the backbone of tumorigenesis. Mutations in pivotal genes—including APC, KRAS, and TP53—disrupt the regulatory machinery of cell growth and apoptosis. Additionally, aberrations in signaling networks such as WNT and TGF-β pathways exacerbate malignant transformation. Intriguingly, heterogeneity within CRC tumors is categorized into molecular subtypes—microsatellite instability (MSI), chromosomal instability (CIN), and consensus molecular subtypes (CMS)—each with distinct biological behaviors and prognostic implications. This granular understanding paves the way for precision diagnostics and tailored therapeutic interventions.

Epidemiological data underscore the multifactorial etiology of CRC, where both genetic predispositions and environmental exposures interplay. Risk elements such as advancing age, hereditary syndromes including Lynch syndrome and familial adenomatous polyposis, and chronic conditions like inflammatory bowel disease create vulnerability to malignant transformation. Concurrently, lifestyle factors wield significant influence; sedentary habits, tobacco usage, excessive alcohol consumption, obesity, and diets rich in red and processed meats elevate CRC risk. Emerging research also implicates complex alterations in gut microbiota composition and persistent inflammatory states as catalysts in colorectal carcinogenesis, revealing new horizons for innovative preventive strategies.

In the landscape of CRC detection, point-of-care diagnostic modalities have dramatically evolved, striving for accuracy, accessibility, and patient compliance. Non-invasive fecal assays such as the Fecal Occult Blood Test (FOBT) have historically provided initial screening options. However, limitations in specificity and false-positive rates, aggravated by dietary interferences, have catalyzed the development of more sensitive assays. The Fecal Immunochemical Test (FIT), targeting human hemoglobin, supplants FOBT by delivering enhanced specificity without dietary restrictions. Furthermore, fecal DNA testing exploits molecular markers including mutations in KRAS and methylation of BMP3, intensifying diagnostic precision, though challenges in false positives necessitate meticulous clinical interpretation.

Beyond stool-based diagnostics, blood-based biomarkers represent a burgeoning frontier in non-invasive CRC detection. The Septin9 assay, targeting methylated DNA signatures circulating in the bloodstream, epitomizes this approach yet grapples with limited sensitivity in detecting pre-malignant adenomas. Expanding this paradigm, liquid biopsy technologies analyze circulating tumor DNA (ctDNA), providing dynamic insights into tumor genomics and real-time disease monitoring. Despite promising clinical applications, liquid biopsy remains complementary to existing screening frameworks due to constraints in sensitivity and cost-effectiveness.

Endoscopic interventions retain their status as the definitive CRC diagnostic and interventional tools. Colonoscopy, the gold standard, offers direct visualization, enabling both detection and therapeutic excision of polyps, distinctly reducing cancer incidence. However, the invasiveness, requisite bowel preparation, and associated patient discomfort pose significant barriers to widespread screening adherence. Alternative approaches, including sigmoidoscopy and capsule endoscopy, address certain limitations but are constrained by coverage gaps and diagnostic comprehensiveness, particularly for proximal colon lesions.

Radiological techniques complement endoscopic methods, offering non-invasive visualization of the colorectal tract. Computed Tomography (CT) colonography generates three-dimensional images of the colon, facilitating polyp detection without the invasion of traditional endoscopy. Nevertheless, the need for bowel cleansing and potential omission of smaller lesions restrict its applicability. Historic methods such as barium enema have largely receded due to inferior sensitivity and specificity compared to contemporary imaging and endoscopy.

Recent technological advancements are revolutionizing CRC diagnostics by integrating cutting-edge molecular and computational platforms. Single-cell sequencing (SCS) disentangles intratumoral heterogeneity, charting the landscape of genetic alterations at unprecedented resolution, vital for understanding tumor evolution and therapeutic resistance. Complementing this, spatial transcriptomics (ST) contextualizes gene expression within the histological architecture, offering nuanced subtype stratification and potential prognostic biomarkers. Artificial intelligence (AI) applications are redefining endoscopic practice by enhancing polyp detection accuracy, automating histopathological evaluations, and synthesizing multi-omic datasets into comprehensive risk models, heralding a new era of personalized medicine.

Lifestyle modification remains a cornerstone in mitigating CRC risk. Establishing dietary patterns rich in fiber while limiting red and processed meat intake, fostering regular physical activity, and abstaining from tobacco and excessive alcohol consumption significantly decrease disease incidence. In parallel, chemopreventive research explores natural compounds and prebiotics as adjuvants to fortify the intestinal environment and inhibit carcinogenic pathways, potentially complementing traditional prevention paradigms.

Despite the progress in screening technology and understanding CRC biology, substantial hurdles persist in global implementation. Screening adherence varies widely across populations due to socioeconomic factors, access disparities, and public awareness. The lack of uniform international guidelines confounds standardized care delivery. Moreover, current methods insufficiently detect early, flat, or sessile lesions, necessitating innovations that balance sensitivity with minimally invasive patient experiences.

Looking ahead, the integration of multi-omics data with advanced analytics promises transformative potential in CRC management. A precision screening framework combining genetic, epigenetic, proteomic, and metabolomic profiles could identify high-risk individuals with unparalleled specificity. Coupled with AI-driven interpretation, such an approach would enable real-time, adaptive screening intervals, and individualized preventive strategies. Simultaneously, public health initiatives must amplify education and access to catalyze lifestyle changes and equitable screening uptake worldwide.

In conclusion, colorectal cancer remains a formidable health challenge with significant morbidity and mortality on a global scale. However, multidisciplinary advances spanning molecular biology, diagnostic technology, and computational intelligence provide a beacon of hope. By converging innovative screening modalities, personalized interventions, and proactive lifestyle management, the medical community edges closer to the ultimate goal of reducing CRC burden and enhancing patient survival.

Subject of Research: Advancements in screening and point-of-care diagnostics for colorectal cancer

Article Title: An Overview of Advancements in Screening Methods and Point-of-care Diagnostics for Colorectal Cancer

News Publication Date: 28-May-2025

Web References:
https://www.xiahepublishing.com/journal/csp
http://dx.doi.org/10.14218/CSP.2025.00006

Image Credits: Sandip V. Pawar

Keywords: Colorectal cancer, Cancer, Screening, Point-of-care diagnostics, Molecular subtypes, Single-cell sequencing, Artificial intelligence